Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
The same is expected to happen soon for Wegovy, which is made by Novo Nordisk. Hims & Hers hasn’t said what it plans to do in that event, but it could seek to sell the drugs itself. The reaction ...
Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...
Tech billionaire Elon Musk said he is not interested in acquiring the video-sharing app TikTok, and has no plans regarding what he would do if he owned it. Musk made the remarks during a virtual ...
With numerous day trading chart providers available in the market, choosing the right one can be a daunting task. To assist you in this endeavor, Benzinga has compiled a comparison list of some of ...
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Eli Blumenthal was a senior editor at CNET covering the latest in the ever-changing worlds of telecom, streaming and sports. He previously worked as a technology reporter at USA Today. Patrick ...